Internal Medicine, Hematology & Oncology · Montgomery, AL
NPI
1427438530
Since 2015
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
4145 Carmichael Rd
Montgomery, AL, 36106
Phone (334) 273-7000
Groups this clinician bills Medicare through
Medicare paid, 2024
$372K
51,051 services
Medicare patients, 2024
173
Average age 73
Drug cost, 2024
$6.8M
2,027 prescriptions
Company payments, 2025
$643
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nino Aleksidze was code J0897 (injection, denosumab, 1 mg), 4,020 times for 19 patients. In total Nino Aleksidze billed 51,051 services in 88 codes, and Medicare paid $372K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,020 | 19 | $18.67 | $75K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,490 | 15 | $0.09 | $132 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,300 | 11 | $15.99 | $21K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 536 | 11 | $0.07 | $39.61 |
| 96375 Injection Administration | Office | 220 | 21 | $10.57 | $2,324 |
| 36415 Venipuncture Blood Collection | Office | 187 | 74 | $8.61 | $1,609 |
| 99214 Office E&M - Established | Office | 179 | 91 | $84.87 | $15K |
| 96372 Injection Administration | Office | 158 | 44 | $9.71 | $1,534 |
| 96367 Intravenous Infusion, Hydration | Office | 125 | 15 | $19.80 | $2,475 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 118 | 12 | $36.12 | $4,263 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 110 | 19 | $0.63 | $69.62 |
| 96413 Chemotherapy Administration | Office | 99 | 16 | $89.55 | $8,866 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 82 | 20 | $46.44 | $3,808 |
| 96523 Chemotherapy | Office | 73 | 16 | $15.89 | $1,160 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 71 | 18 | $0.89 | $62.92 |
By year: 2022 $126K for 26,214 services; 2023 $220K for 35,742 services; 2024 $372K for 51,051 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 187 | 74 | $8.61 | $1,609 |
Medicare prescription drug claims, 2024
In 2024, the drug Nino Aleksidze prescribed most often to Medicare patients was Xgeva (Denosumab), with 87 prescriptions and refills. In total Nino Aleksidze wrote 2,027 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xgeva Denosumab | 87 | 87 | 15 | $279K |
| Fosaprepitant Dimeglumine Generic | 82 | 82 | 26 | $13K |
| Ondansetron Odt Ondansetron | 78 | 78 | 60 | $3,855 |
| Procrit Epoetin Alfa | 78 | 78 | 15 | $44K |
| Anastrozole Generic | 75 | 205 | 26 | $1,343 |
| Palonosetron Hcl Generic | 73 | 73 | 24 | $7,489 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 68 | 68 | 29 | $1,996 |
| Fulvestrant Generic | 63 | 63 | Under 11 | $48K |
| Neulasta Onpro Pegfilgrastim | 49 | 49 | 17 | $387K |
| Acyclovir Generic | 45 | 63 | 15 | $512 |
| Abiraterone Acetate Generic | 44 | 44 | Under 11 | $141K |
| Prolia Denosumab | 38 | 228 | 25 | $65K |
| Carboplatin Generic | 38 | 38 | Under 11 | $3,917 |
| Lupron Depot Leuprolide Acetate | 38 | 159 | 19 | $314K |
| Calquence Acalabrutinib Maleate | 37 | 37 | Under 11 | $556K |
Brand drugs: 843 claims; generic drugs: 1,184 claims; opioid claims: 144.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nino Aleksidze $643 ($643 in general payments such as food, travel and fees) from 21 companies. The largest payer was Novartis Pharmaceuticals Corporation with $67.47.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 3 | $67.47 |
| Genzyme Corporation SNY | 2 | $54.71 |
| PharmaEssentia USA Corporation 6446.TW | 2 | $52.32 |
| Pfizer Inc. PFE | 3 | $51.82 |
| Abbvie Inc. ABBV | 2 | $42.44 |
| Celgene Corporation BMY | 2 | $39.44 |
| CSL Behring CSL.AX | 1 | $34.25 |
| Astellas Pharma US Inc 4503.T | 2 | $32.63 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $28.16 |
| Deciphera Pharmaceuticals Inc. | 1 | $27.76 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.